Phil Campbell
Research Professor, Biomedical Engineering, Engineering Research Accelerator
Courtesy Appointments, Biological Sciences, Materials Science and Engineering
Phillip Campbell is a Research Professor in the Biomedical Engineering Department and the Engineering Research Accelerator at Carnegie Mellon University. He has courtesy appointments in the Biological Sciences and the Mechanical Engineering Departments. Campbell has over 25 years of experience in multidisciplinary research with both engineers and clinicians to develop unique solutions to a wide variety of complex biomedical problems, including the development of natural-based biomaterials, implant biocompatibility, and tissue engineering. One of his overarching research themes involves understanding and engineering the cellular microenvironment from an endocrine point of view, both in vitro and in vivo. The study encompasses growth factor interstitial transport, interactions with receptors and non-receptor binding proteins, immobilization and proteolytic processing of extracellular matrix bound growth factors and other signaling molecules, and live cell and animal imaging. His research has taken advantage of biopatterned microenvironments to spatially deliver signaling molecules to spatially control cell behavior in vitro and tissue formation in vivo toward musculoskeletal, cardiac, immunological, and cancer applications.
Engineering biological signaling for medical applications
Education
1988 Ph.D., Physiology, Pennsylvania State University
1981 MS, Animal Science, Auburn University
1978 BS, Animal Science, Auburn University
Research Interests
Media mentions
Chemical Engineering
Soy protein research provides entrepreneurial training
Ph.D. student Nader Rezazadeh is developing a novel bioactive scaffold as a wound dressing for chronic wounds. He’s also building a prototype for touch-free application.
CMU Engineering
Carnegie Mellon lands ARPA-H award for implantable bioelectric medicine project
A CMU-led project team secured an award of up to $42M from ARPA-H to accelerate the development of implantable bioelectronic devices that deliver patient-specific therapy and monitor disease status.
CMU Engineering
CMU-led project to fight obesity, Type 2 diabetes receives ARPA-H backing
A CMU-led team of researchers has secured an award of up to $34.9 million from ARPA-H to develop a new bioelectric medicine-based treatment for obesity and Type 2 diabetes patients.
NIH
New grant weaves a silk-based partnership
BME’s Charlie Ren and Phil Campbell have received a five-year, $3.5 million Bioengineering Partnerships with Industry (BPI) grant from the NIH, in partnership with David Vorp of the University of Pittsburgh.
University of Pittsburgh
Campbell and Ren join American Heart Association award project team
The American Heart Association’s 2023 Collaborative Sciences Award will be investigated by a multi-institutional team of researchers, including BME’s Phil Campbell and Charlie Ren.
CMU Engineering
Engineering alumni double team innovation in sport
Two CMU materials science and biomedical engineering alumni are at the forefront of the development of an airless basketball made through additive manufacturing techniques.
CMU Engineering
Microneedles unlock curcumin’s therapeutic potential
Researchers engineer a hybrid system that stabilizes curcumin to target skin diseases.
CMU Engineering
3D printing ice
3D printed ice isn’t as magical as in the movie Frozen, but it has wonderful potential for biomedical engineering and advanced manufacturing.
CMU Engineering
Exosome engineering tech licensed to Coya Therapeutics
An interdisciplinary group of faculty from Carnegie Mellon has licensed a proprietary platform for bioengineering exosomes for drug delivery to Coya Therapeutics, Inc.
CMU Engineering
Collaboration shapes extracellular vesicle retention strategy
Phil Campbell and Charlie Ren present a strategy to spatially control extracellular vesicles and keep them resolute under controlled conditions.
CMU Engineering
CMU and Mayo Clinic to collaborate on transplant innovation
Mayo Clinic and Carnegie Mellon University announced today a research agreement to transform organ transplantation. The institutions will bioengineer innovative approaches to address current barriers in organ transplantation.
CMU Engineering
Uncovering a promising use case for exosomes
New research from Carnegie Mellon University and UPMC explores an innovative case for exosomes: delivering growth factors like bone morphogenetic proteins (BMPs) for bone healing.